Comparison of pooled cohort risk equations and Framingham risk score for metabolic syndrome in a Korean community-based population

摘要

Previous risk assessment guidelines, such as the Adult Treatment Panel III (ATP-III), used a modified Framingham risk score (FRS) to set thresholds for lipid treatment based on one's predicted 10-year risk (10YR) for myocardial infarction or coronary heart disease (CHD) death. In 2013, the American Heart Association/American College of Cardiology guideline reported a new pooled cohort risk equation (PCE) designed to assess the 10YR of atherosclerotic cardiovascular disease (ASCVD) [1], However, there have been some arguments about miscalculations of the new equation such as risk overestiman'on and limitation of performance for diverse ethnics [2,3]. For instance, the new PCE systematically overestimated observed risks by 75-150%, roughly doubling the actual observed risk [3]. And recent study showed that FRS overestimated the risk of CHD in the Korean population where the CHD incidence is low [4]. So we compared the performance of new PCE and old FRS in terms of metabolic syndrome (MetS) in a Korean community-based population. This is the first report about the performance of PCE in an Asian population as far as we know.